Aktie A2ABRD NATCO PHARMA LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen NATCO Pharma Limited

Aktien

A2ABRD

INE987B01026

NATCOPHARM

Markt geschlossen - NSE India S.E.
Andere Börsenplätze
 13:40:48 23.05.2024 		% 5 Tage % 1. Jan.
1.025 INR +2,20 % Intraday Chart für NATCO Pharma Limited +4,29 % +26,34 %
08.05. AstraZeneca, Merck verklagen zum Schutz der Patente für das Krebsmedikament Lynparza MT
08.05. AstraZeneca, Merck verklagen zum Schutz der Patente für das Krebsmedikament Lynparza MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents
AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement
Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit
NATCO Pharma Limited Announces Board Appointments
INDIA STOCKS-Indian shares erase early gains, weighed down by IT stocks
NATCO Pharma Limited Revises Earnings Guidance for the Fiscal Year 2024
Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024
NATCO Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Cellogen Therapeutics announced that it has received $2 million in funding from NATCO Pharma Limited
Floods Disrupt Operations of Natco Pharma's Plant in Tamil Nadu, India
Natco Pharma's Consolidated Profit Soars in Fiscal Q2, Declares Second Interim Dividend
NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023
NATCO Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
US FDA Clears Natco Pharma's Pharmacovigilance Department in Hyderabad, India
Redcliffe Hygiene Private Limited announced that it has received INR 248 million in funding from Rainmatter, Alkemi Growth Capital LLP, NATCO Pharma Limited
Indian Equities End Higher for Sixth Straight Day, Buoyed by Banking, Public Sector Enterprises
Natco Pharma, Three Others Face Antitrust Violation Raps in US; Natco Pharma Shares Drop 3%
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit
Indian shares set to open flat on caution ahead of GDP data
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2ABRD Aktie
  4. Nachrichten NATCO Pharma Limited
  5. Andere Sprachen